A new systematic review highlights a significant gap in the evidence for treating osteoporosis in older men. The paper, published in Archives of Osteoporosis, pooled randomised controlled trials and found that although commonly used pharmacological agents reliably increase bone mineral density, robust proof that they reduce the actual fracture risk in men remains limited.
What the review examined
The international team, led by Marco Antonio Araújo da Rocha-Loures of the Clínica de Reumatismo in Maringá, Brazil, and supported by the Brazilian Society of Rheumatology, set out to identify which interventions — drug or non-drug — reduce fractures and improve bone mineral density in men with primary or secondary osteoporosis. The reviewers performed an exhaustive search across eight major databases, including PubMed, EMBASE, Scopus, the Cochrane Library, Web of Science, SciELO, PEDro and LILACS, and screened additional grey literature.
The team followed the PRISMA reporting framework and used the Cochrane Handbook 6.5 methodology. Analyses were carried out in RStudio 4.3.3 and the risk of bias in trials was evaluated with the Cochrane RoB 2 tool.
Key findings
After screening, reviewers included 12 randomised controlled trials in their synthesis. Those trials comprised:
- 10 pharmacological intervention trials;
- 1 trial of a nutritional supplement;
- 1 trial of an exercise programme.
The pooled study population had a mean age of 60.9 years (standard deviation 5.2 years), and baseline bone loss consistent with established osteoporosis: average T-scores of -2.9 at the lumbar spine and -2.7 at the femoral neck.
| Measure | Value |
|---|---|
| Randomised controlled trials included | 12 |
| Pharmacological trials | 10 |
| Non-pharmacological trials (exercise, supplement) | 2 |
| Mean age | 60.9 years (SD 5.2) |
| Mean T-score lumbar spine | -2.9 |
| Mean T-score femoral neck | -2.7 |
Interpretation and consequences
The reviewers conclude that while bone-building drugs increase bone mineral density in men with osteoporosis, the evidence that these gains translate into fewer clinically important fractures is scarce. Non-pharmacological approaches — specifically exercise and nutritional supplements — were represented by only a single trial each, limiting any confident judgement about their effectiveness in men.
For clinicians and healthcare services, the review signals a need for larger, well-designed trials that measure hard outcomes such as hip and vertebral fractures rather than relying solely on bone density changes. For patients and carers, the findings underline uncertainty about which interventions most reduce the fracture risks that carry the greatest morbidity and mortality.
What this means for men at risk
Osteoporosis has traditionally been framed as a condition mainly affecting women, but the data in the included trials show men presenting with advanced bone loss. That suggests men who are older or have risk factors should not be overlooked for assessment and management. However, the review emphasises that policy and prescribing decisions should account for the limited fracture-prevention evidence in men and the scarcity of trials of lifestyle measures.
Going forward, researchers and funders are urged to prioritise randomised studies in male populations that include fracture endpoints and examine realistic, scalable non-drug interventions alongside pharmacological options. Meanwhile, clinicians must balance the demonstrated effects on bone mineral density with the current uncertainty around fracture outcomes when discussing treatment choices with male patients.
